July 27, 2020 – Sysmex Corporation (Kobe, Japan) announced its plans to continue conducting research and development (R&D) with the goal of expanding target parameters for lab assays and providing reagents for research.
In preparation for a predicted resurgence of COVID-19, an urgent need exists for efforts to establish diagnostic tests that cover the time period spanning from immediately after infection through to treatment and recovery, Sysmex says.
In early July, the company began providing a lab assay service for research on cytokines, which Sysmex says have been “suggested as a useful indicator in monitoring the risk of increasing severity and treatment effects for the novel coronavirus (SARS-CoV-2)” that causes COVID-19.
Sysmex began providing “cytokine measurement for research,” a cytokine lab assay service for research using the chemiluminescence enzyme immunoassay method.
Targeting research institutions, universities, medical institutions and pharmaceutical companies, Sysmex will provide data that can be used to confirm testing methods suitable to such clinical applications as determining the risk of increasing severity and treatment effect, as well as data that can be used for vaccines, antiviral drugs and other drug discovery research.